Pennsylvania Senate Bill SB233

Pennsylvania 2025-2026 Regular Session

• Introduced: 2/4/25
• Refer: 2/4/25

Caption

Prohibiting the preparation, manufacture, sale or distribution of unsafe kratom products and the sale or distribution of kratom products to individuals younger than 21 years of age; providing for duties of Department of Health; and imposing penalties.

Summary

SB233, known as the Kratom Consumer Protection Act, would regulate the preparation, manufacture, sale, and distribution of kratom products in Pennsylvania. The bill prohibits processors and retailers from handling kratom products that are adulterated, contaminated with certain controlled or poisonous substances, contain excessive residual solvents, include more than 2% 7-hydroxymitragynine in the alkaloid fraction, contain synthetic kratom alkaloids, or lack adequate ingredient and use labeling, including a recommended serving size. The bill also sets a minimum age of 21 for the sale or distribution of kratom products. It assigns enforcement authority to the Department of Health, which may adopt regulations to implement the act. Violations would be subject to administrative fines that increase with repeat offenses, and the department could require a plan of correction for noncompliance. Fine revenue would be deposited in the State Treasury and credited to the department for administering and enforcing the law.

Impact

SB233 would add a new state regulatory framework specifically for kratom products, supplementing existing drug and cosmetic laws by creating product standards, age restrictions, and enforcement mechanisms. It would affect kratom processors, retailers, and consumers by imposing manufacturing and labeling requirements, banning certain formulations, and limiting sales to adults 21 and older. The Department of Health would gain explicit oversight and rulemaking authority, and administrative penalties would be available for violations.

Sentiment

Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the bill appears to be framed as a consumer protection and public health measure rather than a punitive drug-control bill. The sponsors from both parties suggest some bipartisan interest in regulating kratom rather than banning it outright. No formal vote history or transcript is available here to show broader legislative support or opposition.

Contention

The main points of potential contention are likely the age restriction, the product-content limits, and the state’s authority to regulate a substance that is legal but controversial. Retailers and kratom advocates may object to the 21-and-over sales limit, the 2% 7-hydroxymitragynine threshold, and the ban on synthetic alkaloids if they believe these rules are overly restrictive or difficult to comply with. Public health supporters are likely to favor the bill’s focus on adulteration, labeling, and consumer safety, while opponents may argue that it could burden lawful businesses or limit adult access to kratom products.